AU2011246851B2 - Methods, compositions and kits for providing a therapeutic treatment - Google Patents

Methods, compositions and kits for providing a therapeutic treatment

Info

Publication number
AU2011246851B2
AU2011246851B2 AU2011246851A AU2011246851A AU2011246851B2 AU 2011246851 B2 AU2011246851 B2 AU 2011246851B2 AU 2011246851 A AU2011246851 A AU 2011246851A AU 2011246851 A AU2011246851 A AU 2011246851A AU 2011246851 B2 AU2011246851 B2 AU 2011246851B2
Authority
AU
Australia
Prior art keywords
cancer
treatment
therapeutic method
thyroid
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2011246851A
Other languages
English (en)
Other versions
AU2011246851A1 (en
Inventor
Osnat Ashur-Fabian
Aleck Hercbergs
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of AU2011246851A1 publication Critical patent/AU2011246851A1/en
Application granted granted Critical
Publication of AU2011246851B2 publication Critical patent/AU2011246851B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2011246851A 2010-04-28 2011-04-28 Methods, compositions and kits for providing a therapeutic treatment Ceased AU2011246851B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32882510P 2010-04-28 2010-04-28
US61/328,825 2010-04-28
PCT/IL2011/000346 WO2011135574A1 (en) 2010-04-28 2011-04-28 Methods, compositions and kits for providing a therapeutic treatment

Publications (2)

Publication Number Publication Date
AU2011246851A1 AU2011246851A1 (en) 2012-11-15
AU2011246851B2 true AU2011246851B2 (en) 2016-07-21

Family

ID=44860959

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2011246851A Ceased AU2011246851B2 (en) 2010-04-28 2011-04-28 Methods, compositions and kits for providing a therapeutic treatment

Country Status (11)

Country Link
US (2) US9655984B2 (enExample)
EP (1) EP2563120B1 (enExample)
JP (1) JP5921529B2 (enExample)
KR (1) KR101841304B1 (enExample)
CN (1) CN102858156B (enExample)
AU (1) AU2011246851B2 (enExample)
BR (1) BR112012027463A2 (enExample)
CA (1) CA2797625C (enExample)
ES (1) ES2791708T3 (enExample)
MX (1) MX2012012479A (enExample)
WO (1) WO2011135574A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX386702B (es) 2014-02-10 2025-03-19 Fred Hutchinson Cancer Center Tratamiento con halogeno de ataque cardiaco y lesion isquemica.
CN105486869A (zh) * 2014-10-08 2016-04-13 江苏维赛科技生物发展有限公司 一种检测动物源食品中甲巯咪唑残留的酶联免疫试剂盒及其应用
US20200222348A1 (en) * 2017-05-08 2020-07-16 Musli Thyropeutics Ltd. Bimodal modified release compositions for cancer treatment
WO2021257806A1 (en) * 2020-06-18 2021-12-23 Fred Hutchinson Cancer Research Center Iodide for treatment of nonthyroidal illness syndrome
CN114605278A (zh) * 2022-02-11 2022-06-10 天津市肿瘤医院（天津医科大学肿瘤医院） T3或其可药用盐在制备脑胶质瘤放化疗药物方面的应用
CN114878840A (zh) * 2022-07-12 2022-08-09 昆明思安生物科技有限公司 磁微粒化学发光测定三碘甲状腺原氨酸试剂盒及检测方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030109690A1 (en) * 1999-09-29 2003-06-12 Human Genome Sciences, Inc. Colon and colon cancer associated polynucleotides and polypeptides
US20030130228A1 (en) * 2002-01-04 2003-07-10 Wei-Jan Chen Prevention of atherosclerosis and restenosis
WO2007030577A2 (en) * 2005-09-08 2007-03-15 Shire Llc Prodrugs of t3 and t4 with enhanced bioavailability

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB851610A (en) 1956-03-07 1960-10-19 Gunther Hillman Method for producing iodine derivatives of thyronine
US4426453A (en) 1980-09-18 1984-01-17 Amersham International Limited Derivatives of iodothyronine compounds and their use in an assay for the free iodothyronine compounds
JPH07116031B2 (ja) 1986-09-24 1995-12-13 株式会社アドバンス 制癌剤
US6017958A (en) 1996-06-04 2000-01-25 Octamer, Inc. Method of treating malignant tumors with thyroxine analogues having no significant hormonal activity
US7074426B2 (en) * 2002-03-27 2006-07-11 Frank Kochinke Methods and drug delivery systems for the treatment of orofacial diseases

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030109690A1 (en) * 1999-09-29 2003-06-12 Human Genome Sciences, Inc. Colon and colon cancer associated polynucleotides and polypeptides
US20030130228A1 (en) * 2002-01-04 2003-07-10 Wei-Jan Chen Prevention of atherosclerosis and restenosis
WO2007030577A2 (en) * 2005-09-08 2007-03-15 Shire Llc Prodrugs of t3 and t4 with enhanced bioavailability

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
RABER, W., et al., European Journal of Endocrinology, 2000, vol. 142, pages 117-124 *

Also Published As

Publication number Publication date
AU2011246851A1 (en) 2012-11-15
MX2012012479A (es) 2013-07-03
EP2563120A4 (en) 2015-05-13
BR112012027463A2 (pt) 2015-09-29
EP2563120A1 (en) 2013-03-06
US20170274104A1 (en) 2017-09-28
EP2563120B1 (en) 2020-02-26
JP5921529B2 (ja) 2016-05-24
CA2797625A1 (en) 2011-11-03
US10398789B2 (en) 2019-09-03
KR20130103336A (ko) 2013-09-23
JP2013525422A (ja) 2013-06-20
US9655984B2 (en) 2017-05-23
ES2791708T3 (es) 2020-11-05
US20130129615A1 (en) 2013-05-23
CA2797625C (en) 2019-08-20
CN102858156B (zh) 2015-09-23
WO2011135574A1 (en) 2011-11-03
KR101841304B1 (ko) 2018-03-22
CN102858156A (zh) 2013-01-02

Similar Documents

Publication Publication Date Title
US10398789B2 (en) Methods, compositions and kits for providing a therapeutic treatment
US20090137683A1 (en) Anticancer effect enhancer
KR20060097000A (ko) 화학요법제와 ｖｅｇｆ 수용체 저해제의 배합물
ES2881928T3 (es) Profármacos de etopósido para su uso en el direccionamiento a las células madre cancerosas
Wang et al. Dual PLK1 and STAT3 inhibition promotes glioblastoma cells apoptosis through MYC
AU2008354754B2 (en) On01910. Na enhances chemotherapeutic agent activity in drug-resistant tumors
Liu et al. Rapamycin liposomes combined with 5-fluorouracil inhibits angiogenesis and tumor growth of APC (Min/+) mice and AOM/DSS-induced colorectal cancer mice
KR101843985B1 (ko) 암을 치료하기 위한 조성물과 방법
US10751352B2 (en) Pharmaceutical composition for preventing or treating cancer
KR20040048992A (ko) 선택적 사이클로옥시게나제-2 억제제를 포함하는 조합물
KR101901001B1 (ko) PPAR-β 길항제를 포함하는 항암 효과 증진용 약학적 조성물
CN107569485A (zh) 一种治疗braf抑制剂耐药型黑色素瘤的复方制剂
CN108503676B (zh) 用于癌症治疗的果糖类似物及其组合物
KR102509715B1 (ko) 암의 전이 억제 및 치료용 조성물
WO2019138203A1 (fr) Composition comprenant l'hydroxychloroquine et utilisation therapeutique
CN114010653B (zh) 包括人参皂苷Rg1和岩藻多糖的组合物在制备降低组织因子的表达的药物中的应用
AU2010336256B2 (en) Antitumor Agent or Postoperative Adjuvant Chemotherapeutic Agent for Hepatocellular Carcinoma Treatment
JP2010163426A (ja) ホスホジエステラーゼ５阻害剤とアルギニンを含有する医薬組成物
RU2724341C1 (ru) Комбинированная композиция для предупреждения или лечения рака, содержащая производные бензофенонтиазола в качестве vda и ингибитор топоизомеразы
CN104434924B (zh) 曲美替尼在制备逆转肿瘤多药耐药性药物中的应用
Li et al. Oxaliplatin combined with S-1 capsule in the treatment of 62 cases with advanced gastric cancer
Nakatani et al. Effects of Combination Chemotherapy with Cepharanthin on Oral Squamous Cell Carcinoma
CN119792538A (zh) 胶质母细胞瘤的新的治疗方法
Gusev et al. Primary Neuroprotection

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired